Work

Long-Term Reduction of Relapse Rate and Confirmed Disability Progression After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis

Year: 2020

Type: article

Source: Multiple Sclerosis and Related Disorders

DOI: 10.1016/j.msard.2019.11.068

Authors: Riadh Gouider, Gavin Giovannoni, Ludwig Kappos, Stephen L. Hauser, Xavier Montalban, Harold Koendgen, Kalpesh Prajapati, Marianna Manfrini, Jerry S. Wolinsky

Institutions: Faculté de médecine de Tunis, Tunis El Manar University, Queen Mary University of London, University of Basel, University Hospital of Basel, University of California, San Francisco, University of Toronto, F. Hoffmann-La Roche AG, Vall d'Hebron Hospital Universitari, The University of Texas Health Science Center at Houston

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3011600802

FWCI: 0.161

Cites:

Cited by: 1

Related to: 10